10:42 ET Bid has moved up to 7.55MM @ .18

10:42 ET Bid has moved up to 7.55MM @ .18
Ask staying same at 1.1938MM @ .185
Snapshot
Charts
News
Options
Analyst Research
Fundamentals
Earnings
Insider Activity

Last Price
$0.180
Today’s Change
+0.0021 (+1.18%)
Bid x Size
0.180 x7,550,000
Ask x Size
0.185 x1,193,800
Day’s Range
0.171 - 0.185
Volume
135,162
OTCQB Real Time Quote Last Trade as of 10:24 AM ET 7/2/19
Extended Hours Quote and Chart ShowHide
Open
0.185
Previous Close
0.1779
52-Week Range
0.070 - 0.64
12/31/18 -7/6/18
Avg Volume (10 days)
270,748
P/E (Trailing 12 mo.)
0.0x
EPS (Trailing 12 mo.)
-0.07364
Next Earnings Date
--
Market Cap
34.2 M
Shares Outstanding
192.1 M
Beta
-0.1
Dividend Yield
--
Dividend
--
Ex-Dividend Date
--
Dividend Payable Date
--

1D
5D
3M
1Y
3Y
5Y

Advanced Chart Historical Quote

Analyst Research
More
No TipRanks analyst consensus available.

Powered by TipRanks
There is no Credit Suisse report available.
There is no Thomson Reuters report available.
There is no Morningstar report available.
There is no SmartConsensus report available.
Technical Research
There is no Market Edge report available.
Technical Analysis
Latest Headlines


Latest Headlines
Press Releases
Commentary & Blogs

Innovation Pharmaceuticals Signs Agreement for Advanced Oral Tablet Technology in Treating Inflammatory Bowel Disease
GlobeNewswire 6/6/19 9:30 AM ET
Blogger Sentiment
No TipRanks blogger sentiment available.

Powered by TipRanks
IPIX Company Overview
Innovation Pharmaceuticals Inc., formerly Cellceutix Corporation, is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies with oncology, dermatology and antimicrobial applications. The Company owns the rights to various drug compounds, including Kevetrin (thioureidobutyronitrile), which is its anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis, and Brilacidin, which is its drug in a class of compounds known as defensin-mimetics. The Company's clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Prurisol for the treatment of psoriasis, and Brilacidin for treatments of skin infections, prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative proctitis. The Company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics and inflammatory disease.

Company Contact

Headquarters

100 Cummings Ctr Ste 151b
Beverly, MA 01915-6117

http://www.cellceutix.com/
Quick Links

Add to Watchlist
Historical Quote
View Industry Peers
View My Balances
View My Portfolios
View My Orders